Needham analyst Mike Matson reiterated a Hold rating on Zimmer Biomet (NYSE: ZBH).The analyst commented: "ZBH's 2Q26 revenue and EPS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE